作者
Desmond Curran, Sean Matthews, Eliazar Sabater Cabrera, Silvia Narejos Pérez, Lina Pérez Breva, Mika Rämet, Laura Helman, Dae Won Park, Tino F Schwarz, Isabel Maria Galan Melendez, Axel Schaefer, Nathalie Roy, Brigitte Stephan, Daniel Molnar, Lusine Kostanyan, John H Powers III, Veronica Hulstrøm
发表日期
2024/2
期刊
Influenza and Other Respiratory Viruses
卷号
18
期号
2
页码范围
e13236
简介
Background
Respiratory syncytial virus (RSV) is a contagious pathogen causing acute respiratory infections (ARIs). Symptoms range from mild upper respiratory tract infections to potentially life‐threatening lower respiratory tract disease (LRTD). In adults ≥60 years old, vaccine efficacy of a candidate vaccine for older adults (RSVPreF3 OA) was 71.7% against RSV‐ARI and 82.6% against RSV‐LRTD (AReSVi‐006/NCT04886596). We present the patient‐reported outcomes (PROs) from the same trial at the end of the first RSV season in the northern hemisphere (April 2022).
Methods
In this phase 3 trial, adults aged ≥60 years were randomized (1:1) to receive one dose of RSVPreF3 OA vaccine or placebo. PROs were assessed using InFLUenza Patient‐Reported Outcome (FLU‐PRO), Short Form‐12 (SF‐12), and EuroQol‐5 Dimension (EQ‐5D) questionnaires. Peak FLU‐PRO Chest/Respiratory scores …
学术搜索中的文章
D Curran, S Matthews, ES Cabrera, SN Pérez… - Influenza and Other Respiratory Viruses, 2024